My Support, My Resources
Beginning a new therapy can be hard. We strive to provide you with useful information and tools that will help you along your treatment journey. This information may help you get the most out of your treatment:
ICLUSIG 1Point™
A Single Point of Connection for Access and Patient Support
When you need support, you can turn to ICLUSIG 1Point™. ICLUSIG 1Point™ is a program designed to provide patients and caregivers with information about financial assistance and support for ICLUSIG® (ponatinib) treatment.
Access: Coverage and reimbursement support
A Patient Access Specialist can work with you and your health care provider's office to conduct a benefits investigation and to provide you both with details on your drug coverage and options.
Afford: Financial assistance
Regardless of your insurance status, ICLUSIG 1Point™ can help identify an array of financial assistance programs for which you may be eligible.
Assist: Support throughout treatment
ICLUSIG 1Point™ is committed to supporting you throughout your treatment by offering a wide range of support services to get you the information you need and assist with day-to-day concerns associated with your treatment.
To learn more on how you can enroll in ICLUSIG 1Point™, visit the ICLUSIG 1Point™ website or call 1-844-T1POINT (1-844-817-6468).
Looking for information about CML and ICLUSIG?
Treatment Tools
Helpful links, tools, and information for patients with CML and Ph+ ALL.
Understanding your condition and its treatment can be difficult. Even grasping the basics can be confusing. That’s why we’ve put together the following materials and links to help you find information and support resources:
For patients taking ICLUSIG® (ponatinib):
Patient Medication Guide: A full description of the most important information you should know about ICLUSIG.
ICLUSIG 1Point™: ICLUSIG 1Point™ is dedicated to providing patients and caregivers with information, financial assistance, and support for ICLUSIG treatment.
Patient Treatment Road Map: A guidebook that provides an overview of why your doctor chose ICLUSIG for you, what to expect from treatment, and more.
For all patients
Not sure you understand a particular term on this website?
Glossary of terms
There are many unique words, terms, and abbreviations used within the CML community. Learning them will make it easier to have a comfortable conversation with others, particularly your doctor, about your condition.
Keep in mind that this information can’t substitute for a doctor’s medical advice. Consult with your doctor on how these terms may apply to you.
Accelerated phase CML (AP-CML)
Accelerated phase is characterized by higher levels of white blood cells and blast cells (immature white blood cells). More symptoms may appear. If not treated, AP-CML can progress to blast phase CML (BP-CML).
BCR-ABL gene
Mutations to this gene, which produces the BCR-ABL protein, are one of the main causes of resistance to treatment for CML and Ph+ ALL. These mutations cause the shape of the BCR-ABL protein to change, preventing therapies from effectively binding.
BCR-ABL transcripts
Transcription is the biological process by which genes copy and reproduce themselves. BCR-ABL transcripts are copies of the mutated gene that causes CML.
Blast cell
A blast cell is an immature white blood cell that normally represents an early phase of cell development in the bone marrow. When you have CML, a genetic abnormality causes your bone marrow to produce too many blasts, which then crowd out healthy cells in the blood.
Blast phase CML (BP-CML)
This is the most advanced phase of CML. Patients in blast phase have even higher levels of white blood cells and blast cells. More severe symptoms such as bleeding, fever, and fatigue may develop.
Chromosomal tests
Tests that monitor chromosomes within the bone marrow or blood.
Chromosome
A chromosome is a structure within the nucleus of a cell that contains a molecule of DNA that transmits genetic information.
- Each organism of a species normally has a characteristic number of chromosomes. For humans, the normal number is 46
- The chromosomal mutation leading to CML involves chromosomes number 9 and 22
Chronic phase CML (CP-CML)
Chronic phase is the earliest phase of CML. Patients in CP have unusually high levels of white blood cells. Symptoms are generally mild and may include fatigue, weakness, shortness of breath, fullness or early satiety, and weight loss.
Complete cytogenetic response (CCyR)
No cells in the sample have the Ph chromosome.
Complete hematologic response (CHR)
There are no leukemic blast cells in your blood, and your blood cell counts have returned to within the normal range.
Hematologic tests
Tests that monitor blood cell counts.
Intolerance
Intolerance is when a medication causes side effects so bad that they make it too difficult to continue taking the treatment.
Major cytogenetic response (MCyR)
0% to 35% of cells in the sample have the Ph chromosome.
Major hematologic response (MaHR)
There are no leukemic blast cells in your blood, and your blood cell counts may be low or within the normal range.
Major molecular response (MMR)
The number of BCR-ABL transcripts is 1000 times less than the results from the first molecular test.
Molecular tests
Tests that monitor the level of BCR-ABL transcripts in the blood.
Mutational testing
Mutational testing is often performed for CML patients who have become resistant to their TKI therapy. It is used to see if there is a mutation on the BCR-ABL oncogene, including the T315I mutation. Mutational testing is usually done using a sample of blood or bone marrow.
Partial cytogenetic response (PCyR)
PCyR is a response to CML treatment that indicates that between 1% and 35% of the cells in a patient’s blood or bone marrow contain the Philadelphia chromosome and the BCR-ABL gene that causes CML.
Philadelphia (Ph) chromosome
The Philadelphia chromosome is an abnormal chromosome formed when pieces of chromosomes 9 and 22 switch with each other. This forms a longer chromosome 9 and a shorter chromosome 22. The shorter chromosome 22 contains the BCR-ABL protein and is known as the Philadelphia chromosome, which is associated with CML and Ph+ ALL.
Resistance
Either an initial lack of response to a new drug or a loss of response over time.
Tyrosine kinase inhibitors (TKIs)
A TKI is a drug that interferes with cell communication and that may prevent uncontrolled tumor growth. Some tyrosine kinase inhibitors are used to treat cancer.